Breaking News
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
January 16, 2018 - Aztec apocalypse found to be Salmonella outbreak
January 16, 2018 - Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy
January 16, 2018 - Three Ineffective Institutional Approaches to Quality Improvement in Healthcare
January 16, 2018 - New technology accelerates autism diagnosis and treatment
January 16, 2018 - Preterm babies likely to experience delays in auditory brain development, study reveals
January 16, 2018 - Research sheds new light on genetic, environmental factors that promote prostate cancer metastasis
January 16, 2018 - Mitochondrial impairment may actually protect the brain in Parkinson’s disease, study shows
January 15, 2018 - Energy drinks can have adverse health effects on youth, study reveals
January 15, 2018 - 60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug Tafenoquine
January 15, 2018 - Wanted: ‘Breathalyzer’ for Cannabis Use
January 15, 2018 - Surfers more likely to get antibiotic resistant E. coli in their guts
January 15, 2018 - “Baby brain” a real clinical entity finds study
January 15, 2018 - Whole of Britain to be put on a diet plan come March
January 15, 2018 - Neighborhood Deprivation Linked to Heart Failure
January 15, 2018 - Omega-3 and Omega-6 fatty acid intake may affect lupus outcomes
January 15, 2018 - Scientists discover new enzyme that could reduce obesity rates
January 15, 2018 - Evidence suggests two patterns of early symptoms precede and predict later BD risk
January 15, 2018 - Harm minimization approach for smoking cessation with e-cigarettes
January 15, 2018 - Surgery or Antibiotics for Appendicitis? Here’s What Patients Chose
January 15, 2018 - ASH: Frailty Screening Tool Guides Therapy in Elderly
January 15, 2018 - Study shows video games could cut dementia risk in seniors
January 15, 2018 - Common Food Additive Promoting C. diff?
January 15, 2018 - Mild traumatic brain injury causes long-term damage in mice
January 15, 2018 - Circadian clock proteins set the pace of plant growth
January 15, 2018 - Two proteins shown to regenerate brain in Parkinson’s disease
January 15, 2018 - Jotting down tasks may ease falling asleep, study says
January 15, 2018 - Chi-Med Initiates Fruquintinib U.S. Clinical Trials
January 15, 2018 - Cell-Free DNA May Help Pinpoint Breast Ca Survival
January 15, 2018 - What goes on inside a medically supervised injection facility?
January 15, 2018 - Research provides new model to better ascertain HIV mortality rates in Zambia
January 15, 2018 - Genetic analysis can enhance outcomes of depression treatment
January 15, 2018 - Variations in bacterial strains can trigger varying immune responses, study states
January 15, 2018 - TherapeuticsMD Announces Resubmission of New Drug Application for TX-004HR
January 15, 2018 - HIV Vaccine Shows ‘Positive Signal’ in Small Study
January 15, 2018 - Researchers demonstrate RAS dimers are essential for cancer
January 15, 2018 - Groundbreaking report highlights plan to end bowel cancer
January 15, 2018 - Doc Aspires to Bring ‘Medicine the Musical’ to Off-Broadway
January 15, 2018 - Does an exploding brain network cause chronic pain?
January 15, 2018 - Researchers use novel PET tracer to assess myelin damage in mouse models of MS
January 15, 2018 - Survival strategy of mRNAs during sugar deficiency in the cell
January 15, 2018 - Hormone Therapy May Ease Depression Linked to Menopause
January 15, 2018 - Pain Sensitization Declines After Bariatric Tx in Obese Patients
January 15, 2018 - C7 nerve transfer improves function in spastic arm paralysis
January 15, 2018 - Australian kids are drinking and smoking far less than before
January 15, 2018 - Worsening of anxiety symptoms may be early indicator of Alzheimer’s disease
January 15, 2018 - Early testing for influenza symptoms can limit severe, life-threatening disease
January 15, 2018 - Exposure to estrogen-mimicking compounds may reverse effects of breast cancer treatment
January 15, 2018 - Lipids May Play Key Role in Abdominal Aneurysm
January 15, 2018 - Raw Dough’s a Raw Deal and Could Make You Sick
January 15, 2018 - Thinking about germs makes people concerned about how they look
January 15, 2018 - Pitt scientists develop new guidelines to alleviate EMS personnel fatigue
January 15, 2018 - Discovery suggests new approach for targeting most-wanted molecular culprits in cancer
January 14, 2018 - Rhizen Pharmaceuticals S.A. Receives FDA Orphan-Drug Designation for Tenalisib (RP6530) for Treatment of Peripheral T-Cell Lymphoma (PTCL)
January 14, 2018 - Adding Enzyme to Chemo Combo Improves Outcomes in Pancreatic CA
January 14, 2018 - Research suggests ways to help mentally ill in Ghana’s prayer camps
January 14, 2018 - U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer
January 14, 2018 - Availability of qualified nurses in hospitals affects patient satisfaction
January 14, 2018 - Prostate cancer’s gene-determined ‘immune landscape’ dictates tumor progression
January 14, 2018 - Online CME: Is This Your First Choice?
A Little Dab’ll Do Ya to Prevent Squamous Cell Carcinoma

A Little Dab’ll Do Ya to Prevent Squamous Cell Carcinoma

image_pdfDownload PDFimage_print

Action Points

  • Topical fluorouracil (5%, applied twice daily to the face and ears for up to four weeks) reduced the risk of squamous cell carcinoma (SCC) requiring surgery by 75% in the first year after use, in a randomized trial of 932 veterans at high risk for keratinocyte carcinoma (SCC and basal cell carcinoma).
  • Note that risk of BCC was similar in the first year in the fluorouracil group and in controls, and there was no difference in risk of either SCC or BCC over the full four-year trial period.

A randomized trial of 932 veterans at high risk for keratinocyte carcinoma showed that topical fluorouracil, 5%, applied twice daily to the face and ears for up to four weeks, reduced the risk of squamous cell carcinoma (SCC) requiring surgery by 75% in the first year after use (risk ratio 0.25, P=0.002), researchers found.

Risk of basal cell carcinoma (BCC), however, was similar at about 10% in the first year in the fluorouracil group and in controls, reported Martin A. Weinstock, MD, PhD, of Providence Veterans Affairs Medical Center in Rhode Island, and colleagues online in JAMA Dermatology.

There was no difference in risk of keratinocyte carcinoma in year 1 and the risk of either SCC or BCC was not reduced over the full four-year trial period. Moreover, patients reported a high rate of severe or moderate adverse effects during treatment.

Nevertheless, most participants said they would repeat the treatment if it was shown to be conclusively effective in preventing skin cancer. These findings suggest a possible role for the annual use of topical fluorouracil chemoprevention in special high-risk populations, including patients who have received transplants, the investigators said.

In the United States, keratinocyte carcinoma accounts for about three-quarters of all cancers, and incidence is rising.

“It is reasonable at this point to consider the use of a standard and perhaps annual course of topical fluorouracil, 5%, to the face and ears for the reduction of SCC risk in high-risk populations, and potentially for a reduction in need for Mohs surgery,” Weinstock and colleagues wrote. “Topical fluorouracil is the first agent we know of that demonstrates extended post-treatment effects in SCC chemoprevention.”

No “rebound” effect of increased SCCs was observed in the fluorouracil group in year 2 or subsequently. However, the investigators did note a large 49% reduction in the number of fluorouracil group participants who had Mohs surgery treatments for BCCs and keratinocyte carcinoma compared to controls.

More study is also required to better define the effect of fluorouracil on BCC risk, including BCC that requires Mohs surgery, they said.

For the the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial, participants were recruited from May 2009 through September 2011, and followed through June 2013. Almost all were male (98%) with a median age of 70 years.

Treatment and control groups were matched for demographic characteristics, military service periods, sunburn, Fitzpatrick skin type, sun protection use during the study, and medical histories, including at least two prior BCCs or SCCs.

In addition to the fluorouracil treatment, participants also received a 30 SPF sunscreen and received education about skin cancer, sunscreen, and sun safety.

Median follow-up was 2.8 years and 97% of participants in each group were followed for at least one year after randomization.

In the first year, 95 of 299 participants (32%) developed BCC and 25 of 108 participants (23%) developed SCC including five participants (1%) in the fluorouracil group and 20 (4%) in the control group.

The only difference in BCC risk was seen in year 2 of the study, the study authors report. Notably, this risk was higher in the fluorouracil group (87 versus 59 tumors; P=0.01).

There were no differences in BCC risk in years 1, 3, or 4 and the only difference in SCC risk was the significant decrease seen in year 1.

Among 27 participants in the control group, 36 underwent Mohs treatment for BCCs and 14 participants in the fluorouracil group underwent Mohs for 17 BCCs (RR 0.51, P=0.045). Five patients in the control group and three in the fluorouracil group were treated for SCCs requiring Mohs surgery.

In year 1, the RR for keratinocyte carcinoma was 0.51 (P=0.02) and there were no differences between groups over the 4-year study period.

Weinstock and colleagues acknowledged the adverse effects of fluorouracil and consequently evaluated participants’ completion of the medication course, the occurrence of adverse events, and patients’ attitudes toward using the drug in the future.

A total of 85% of fluorouracil participants (397 of 468) and 96% of controls completed at least 28 doses of the study medication. However, only 31% of those taking fluorouracil group completed 56 doses compared to 81% of controls.

After 2 weeks, 92% of participants in the fluorouracil group reported erythema, and 61% had mild-to-moderate crusting.

After six months, 21% in the fluorouracil group retrospectively rated treatment adverse effects as “severe,” 40% as “moderate,” 25% as “mild,” and 14% as “none.” At the six-month check-in, 76% of controls reported no adverse effects.

When surveyed at six and 12 months, 87% of fluorouracil group participants said they would repeat treatment if it was shown to be effective in reducing future skin cancers.

“This trial demonstrates a proactive approach that is effective,” the study authors point out. Although annual application may be needed since the effect appears to last for only a year, clinical experience indicates there may be fewer adverse effects with the second and third application, they noted. This may be due to improvement in keratinocytic dysplasia following application to sun-damaged areas.

More study is needed to more precisely define the groups that would most benefit, they added.

A randomized study has shown that daily ingestion of a large dose of nicotinamide (NNA) can reduce the risk of SCC and BCC by 23%. However, this beneficial effect disappears as soon as dosing stops, Weinstock and colleagues said. Notably, the results indicated that nicotinamide may simultaneously increase the risk of the most aggressive types of BCC and SCC.

Study limitations include the potential unblinding of participants (but not investigators) due to the adverse effects of treatment as well as potential limited generalizability to women and younger individuals.

This study was supported by the U.S. Department of Veterans Affairs. Lead study author Weinstock reported relationships with AbbVie, Castle, and Celgene. One co-author reported a relationship with Pfizer. Other study authors declared they had no potential conflicts of interest.

2018-01-04T16:30:00-0500

Tagged with:

About author

Related Articles